Cancer and the potential place for growth hormone receptor antagonist therapy

Growth Horm IGF Res. 2001 Jun;11 Suppl A:S121-3. doi: 10.1016/s1096-6374(01)80020-4.

Abstract

Pegvisomant is a recombinant protein, structurally similar to natural human growth hormone (GH), which is capable of binding to the GH receptor as a competitive antagonist. As well as being evaluated for the treatment of acromegaly, pegvisomant is being investigated as a possible antineoplastic agent, initially in mice. So far, in vitro efficacy against meningioma and in vivo efficacy against colon and breast cancer cell lines have been examined.

Publication types

  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / metabolism
  • Human Growth Hormone / analogs & derivatives
  • Human Growth Hormone / metabolism
  • Human Growth Hormone / pharmacology*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Meningioma / drug therapy
  • Mice
  • Neoplasms / drug therapy*
  • Receptors, Somatotropin / antagonists & inhibitors*
  • Tumor Cells, Cultured

Substances

  • Receptors, Somatotropin
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • pegvisomant